INOVIO PHARMACEUTICALS, INC. — Form 8-K
Filed November 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Inovio received accelerated FDA approval on October 30, 2026 for VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), the first FDA-approved DNA medicine, for reducing surgery frequency in RRP patients. The company completed a public offering raising $80.5M net proceeds in November 2026 to support commercialization. VOCERYQ will ship in ~60 days and achieve full commercial launch in Q1 2027; Inovio projects cash runway into late Q4 2027 including the offering proceeds and an estimated $21M Q4 2026 burn rate.
Why this rating
First approved product transforms loss-making biotech into commercial stage; $80.5M capital raise is ~108% of $74.3M market cap, materially extending runway. Revenue upside and validating DNA platform are significant, but execution risk (confirmatory study, market adoption, manufacturing) and modest RRP patient population (~25K US) temper transformational potential.
Tradability signal
NO TRADE
No trade: the filing reads positive but the market is selling it (-6.6% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.44 ▲ 2.91% | at our read · unknown $1.40 | +10 min · unknown $1.40 ▲ 0.21% | +30 min · unknown $1.35 ▼ 3.57% | +1 hr · unknown $1.35 ▼ 3.21% | +4 hrs · unknown $1.42 ▲ 1.43% |
The stock had already moved -2.83% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.